Technical Analysis for PER - Percheron Therapeutics Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.082 | -3.53% | -0.003 |
Earnings due: Nov 14
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | -3.53% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.53% | |
| MACD Bullish Signal Line Cross | Bullish | -3.53% | |
| Inside Day | Range Contraction | -3.53% | |
| Wide Bands | Range Expansion | -3.53% | |
| 20 DMA Resistance | Bearish | -4.65% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.65% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 11 hours ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 11 hours ago |
| Fell Below Previous Day's Low | about 11 hours ago |
| 20 DMA Resistance | about 11 hours ago |
| Down 2% | about 11 hours ago |
Get this analysis on your stocks daily!
Percheron Therapeutics Limited Description
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. The company was incorporated in 2000 and is based in Toorak, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Diseases Pharmaceuticals Asthma Multiple Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.14 |
| 52 Week Low | 0.052 |
| Average Volume | 2,972,577 |
| 200-Day Moving Average | 0.082 |
| 50-Day Moving Average | 0.093 |
| 20-Day Moving Average | 0.084 |
| 10-Day Moving Average | 0.081 |
| Average True Range | 0.005 |
| RSI (14) | 46.81 |
| ADX | 22.13 |
| +DI | 28.514 |
| -DI | 27.838 |
| Chandelier Exit (Long, 3 ATRs) | 0.124 |
| Chandelier Exit (Short, 3 ATRs) | 0.093 |
| Upper Bollinger Bands | 0.108 |
| Lower Bollinger Band | 0.060 |
| Percent B (%b) | 0.45 |
| BandWidth | 57.245 |
| MACD Line | -0.004 |
| MACD Signal Line | -0.004 |
| MACD Histogram | 0.0004 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.088 | ||||
| Resistance 3 (R3) | 0.089 | 0.087 | 0.087 | ||
| Resistance 2 (R2) | 0.087 | 0.086 | 0.087 | 0.087 | |
| Resistance 1 (R1) | 0.085 | 0.085 | 0.084 | 0.084 | 0.086 |
| Pivot Point | 0.083 | 0.083 | 0.083 | 0.083 | 0.083 |
| Support 1 (S1) | 0.081 | 0.082 | 0.080 | 0.080 | 0.078 |
| Support 2 (S2) | 0.079 | 0.081 | 0.079 | 0.077 | |
| Support 3 (S3) | 0.077 | 0.079 | 0.077 | ||
| Support 4 (S4) | 0.076 |
